Trevi Therapeutics Inc [TRVI] stock is trading at $10.86, up 1.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TRVI shares have gain 3.13% over the last week, with a monthly amount glided 9.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on August 21, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $18. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on July 01, 2025, and set its price target to $25. On May 28, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $21 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $29 on March 10, 2025. Needham reiterated its recommendation of a Buy and raised its price target to $25 on March 10, 2025. H.C. Wainwright reiterated a Buy rating for this stock on December 12, 2024, and upped its price target to $7.50.
Trevi Therapeutics Inc [TRVI] stock has fluctuated between $2.36 and $11.83 over the past year. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $10.86 at the most recent close of the market. An investor can expect a potential drop of -26.34% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -352.89%, Pretax Profit Margin comes in at -324.28%, and Net Profit Margin reading is -323.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.41 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.55 points at the first support level, and at 10.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.08, and for the 2nd resistance point, it is at 11.29.
Ratios To Look Out For
For context, Trevi Therapeutics Inc’s Current Ratio is 22.42. As well, the Quick Ratio is 22.42, while the Cash Ratio is 12.67.
Transactions by insiders
Recent insider trading involved Delfini Lisa, Officer, that happened on Oct 07 ’25 when 0.11 million shares were purchased. Officer, Delfini Lisa completed a deal on Oct 03 ’25 to buy 40000.0 shares. Meanwhile, Officer Delfini Lisa bought 0.31 million shares on Aug 27 ’25.
